Figure 5
Rosiglitazone (Rosi) prevents macrophage DNMT1-potentiated proinflammatory cytokine production and AS development.
(a) Plasma cytokine levels of the ApoE−/− or macrophage DNMT1 transgenic (TgDNMT1) ApoE−/− mice treated with Rosi (i.p., 12 mg/100 g bw/2 days) and AD for 12 weeks (n = 6, *P < 0.05 and **P < 0.01). (b) mRNA levels of the inflammation-related genes in the macrophages isolated from the arterial plaques of the mice described in (a) (n = 6, *P < 0.05 and **P < 0.01). (c) mRNA levels of the inflammation-related genes in the ox-LDL (50 nM) and/or Rosi (50 nM)-stimulated PMs isolated from the WT or TgDNMT1 mice. (n = 6, *P < 0.05 and **P < 0.01). (d) Representative cross-sectional image of Oil Red O-stained aortic sinuses from the indicated mice treated with Rosi (i.p., 12 mg/100 g bw/2 days) and fed an AD for 12 weeks, as well as the quantification of the aortic lesion area.
